Related Experiment Video
Updated: Jul 14, 2026
Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
Published on: November 9, 2018
Treatment response and colonic gene expression in patients with Crohn's disease
Claudio Csillag1, Rehannah Borup, Jørgen Olsen
1Department of Gastroenterology C, Herlev Hospital, University of Copenhagen, Herlev, Denmark. claudio@dadlnet.dk
Objective:
Responses and adverse events to medication vary greatly among patients with Crohn's disease (CD). The aim of this study was to investigate whether global gene expression profiles could predict such responses and possible side effects.
Material And Methods:
Tissue specimens from the descending colon were obtained from 32 CD patients (in 18 patients from areas without inflammation and in 14 patients from inflamed areas). Gene profiling was done using the Affymetrix Human Genome U133 Plus 2.0 GeneChip array. Hybridization data were analyzed with dChip software.
Results:
There were no differentially expressed genes between six patients who responded well to azathioprine and four who did not. No differences were found between 12 patients with adverse events to azathioprine and 9 patients who tolerated this drug. Sixteen patients who were not glucocorticoid-dependent had no differentially expressed genes as compared with 15 glucocorticoid-dependent patients. Six patients who responded well to infliximab had only one differentially expressed gene as compared to four patients who did not.
Conclusions:
DNA microarray analyses did not show differentially expressed genetic profiles from colonic mucosal cells obtained from groups of patients classified according to therapeutic criteria.
Insights
Global gene expression profiles in Crohn's disease (CD) patients did not predict medication response or side effects. DNA microarray analysis of colonic mucosal cells revealed no significant genetic differences based on therapeutic outcomes.
Area of Science:
- Gastroenterology
- Molecular Biology
- Pharmacogenomics
Background:
- Patient responses and adverse events to medications for Crohn's disease (CD) exhibit significant variability.
- Identifying biomarkers to predict treatment outcomes in CD is crucial for personalized medicine.
Purpose of the Study:
- To investigate the potential of global gene expression profiles in predicting medication responses and adverse events in Crohn's disease patients.
- To determine if gene expression patterns in colonic tissue correlate with therapeutic efficacy or side effects of CD medications.
Main Methods:
- Colonic tissue specimens were collected from 32 Crohn's disease patients, from both inflamed and non-inflamed areas.
- Gene expression profiling was performed using the Affymetrix Human Genome U133 Plus 2.0 GeneChip array.
- Hybridization data were analyzed using dChip software to identify differentially expressed genes.
Main Results:
- No significant differences in gene expression were observed between patients who responded well to azathioprine and those who did not.
- Analysis revealed no distinct gene expression profiles between patients experiencing adverse events to azathioprine and those who tolerated the drug.
- No differentially expressed genes were found when comparing glucocorticoid-dependent and non-dependent patients, nor between responders and non-responders to infliximab.
Conclusions:
- DNA microarray analysis of colonic mucosal cells did not identify differentially expressed genetic profiles associated with therapeutic criteria in Crohn's disease patients.
- Global gene expression profiling, as assessed by this study, may not be a reliable predictor of medication response or adverse events in CD.
- Further research may be needed to explore other potential biomarkers or methodologies for predicting treatment outcomes in Crohn's disease.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...